Land: Verenigde Staten
Taal: Engels
Bron: NLM (National Library of Medicine)
FERRIC PYROPHOSPHATE CITRATE (UNII: UBY79OCO9G) (FERRIC CATION - UNII:91O4LML611)
Ropack Inc.
FERRIC PYROPHOSPHATE CITRATE
FERRIC CATION 272 mg in 272 mg
PARENTERAL
PRESCRIPTION DRUG
Triferic is an iron replacement product indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD). Triferic is not intended for use in patients receiving peritoneal dialysis. Triferic has not been studied in patients receiving home hemodialysis. None Risk Summary There are no data with Triferic use in pregnant women to inform a drug-associated risk. No teratogenicity was observed in animal reproduction studies with administration of ferric pyrophosphate citrate to pregnant rats and rabbits during organogenesis at doses 96 and 128 times, respectively, the maximum recommended human dose (MRHD) of 27.2 mg per dialysis [see Data]. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%–4% and 15%–20%, respectively. Data Animal Data In a fertility and early embryonic development study in female rats, the maternally toxic ferric pyrophosphate citra
Triferic is available in ampules or packets in the following package sizes: Store ampules protected from light in the aluminum pouch at controlled room temperature (20° to 25°C [68° to 77°F]); excursions permitted to 15°to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Store packets at controlled room temperature (20° to 25°C [68° to 77°F]); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].
New Drug Application
TRIFERIC- FERRIC PYROPHOSPHATE CITRATE POWDER ROPACK INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE TRIFERIC SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR TRIFERIC. TRIFERIC (FERRIC PYROPHOSPHATE CITRATE) SOLUTION, FOR HEMODIALYSIS USE TRIFERIC (FERRIC PYROPHOSPHATE CITRATE) FOR SOLUTION, FOR HEMODIALYSIS USE INITIAL U.S. APPROVAL: 2015 INDICATIONS AND USAGE TRIFERIC is an iron replacement product indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD). ( 1) Limitation of Use Triferic is not intended for use in patients receiving peritoneal dialysis. ( 1.1) Triferic has not been studied in patients receiving home hemodialysis. ( 1.1) DOSAGE AND ADMINISTRATION Add one 5 mL ampule of Triferic solution to each 2.5 gallons of bicarbonate concentrate to achieve a concentration of iron (III) in the final hemodialysate of 2 micromolar (110 mcg/L). ( 2.1) Add one 50 mL ampule of Triferic solution to each 25 gallons of bicarbonate concentrate to achieve a concentration of iron (III) in the final hemodialysate of 2 micromolar (110 mcg/L). ( 2.1) Add one packet of Triferic powder to each 25 gallons of bicarbonate concentrate to achieve a concentration of iron (III) in the final hemodialysate of 2 micromolar (110 mcg/L). ( 2.1) DOSAGE FORMS AND STRENGTHS 27.2 mg of iron (III) per 5 mL ampule as Triferic solution (5.44 mg of iron (III) per mL). ( 3) 272 mg of iron (III) per 50 mL ampule as Triferic solution (5.44 mg of iron (III) per mL). ( 3) 272 mg of iron (III) per packet as Triferic powder. ( 3) CONTRAINDICATIONS None (4) WARNINGS AND PRECAUTIONS Hypersensitivity Reactions: Observe for signs and symptoms of hypersensitivity during and after hemodialysis and until clinically stable. ( 5.1) ADVERSE REACTIONS The most common adverse reactions in controlled clinical studies include: headache, peripheral edema, asthenia, AV fistula thrombosis, urinary tract Lees het volledige document